背景介绍 RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression. 产品介绍 RGFP966 is specific for HDAC3, with an IC50 of 0.08 µM and no effective inhibition of any other HDAC at concentrations up to 15 µM.